FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Anand Rathi, BP Equities (BP Wealth), Canara Bank Securities Ltd, Dilip Davda, DRChoksey FinServ Pvt Ltd., Geojit Securities Ltd, Marwadi Shares and Finance Ltd, Mehta Equities, Nirmal Bang, Reliance Securities, SBICAP Securities Limited, Stoxbox by BP Equities Pvt Ltd, Sushil Finance Ltd, Swastika Investmart Ltd and Ventura Securities Limited have given "Apply" recommendation to Emcure Pharma IPO. Capital Market, HENSEX Securities and Master Capital Services Limited have given "May Apply" recommendation to Emcure Pharma IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 15 | 3 | 0 | 0 | 0 |
% | 83.33 | 16.67 | 0.00 | 0.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Anand Rathi | Apply | |
BP Equities (BP Wealth) | Apply | |
Canara Bank Securities Ltd | Apply | |
Capital Market | May Apply | |
Dilip Davda | Apply | |
DRChoksey FinServ Pvt Ltd. | Apply | |
Geojit Securities Ltd | Apply | |
HENSEX Securities | May Apply | |
Marwadi Shares and Finance Ltd | Apply | |
Master Capital Services Limited | May Apply | |
Mehta Equities | Apply | |
Nirmal Bang | Apply | |
Reliance Securities | Apply | |
SBICAP Securities Limited | Apply | |
Stoxbox by BP Equities Pvt Ltd | Apply | |
Sushil Finance Ltd | Apply | |
Swastika Investmart Ltd | Apply | |
Ventura Securities Limited | Apply |
The Captial Market (CapitalMarket.com) rating for Emcure Pharma IPO is 45. Their analysis recommends May subscribe for the IPO.
Reviewer | Rating Score | Rating |
---|---|---|
Capital Market | 45 | May subscribe |
[Dilip Davda] The company is one of the leading pharma company having niche products and serving global markets. It marked growth in its top lines, but bottom line posted declining trends due to higher interest and depreciation costs. Based on FY24 earnings, the issue appears fully priced. Reduction in debt post IPO will improved its bottom line commensurately. Investors may park funds for the medium to longer term. Read detail review...
Emcure Pharmaceuticals Limited peer comparison with similar listed entities. (As on March 31, 2024)
Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
---|---|---|---|---|---|---|---|
Emcure Pharmaceuticals Limited | 27.54 | 27.54 | 163.22 | 21.27 | Consolidated | ||
Dr. Reddy's Laboratories Limited | 335.22 | 335.59 | 1,693.75 | 17.93 | 19.74 | 3.54 | Consolidated |
Cipla Ltd. | 51.05 | 51.01 | 330.78 | 30.10 | 15.43 | 4.64 | Consolidated |
Alkem Laboratories Ltd | 150.19 | 150.19 | 862.46 | 33.86 | 17.41 | 5.90 | Consolidated |
Torrent Pharmaceuticals Ltd. | 48.94 | 48.94 | 202.57 | 57.74 | 24.15 | 13.95 | Consolidated |
Mankind Pharma Limited | 47.75 | 47.68 | 233.73 | 45.30 | 20.43 | 9.24 | Consolidated |
Abbott India Ltd. | 565.28 | 565.28 | 1,740.71 | 47.43 | 32.48 | 15.40 | Consolidated |
J. B. Chemicals & Pharmaceuticals Limited | 35.66 | 34.85 | 188.37 | 50.49 | 18.90 | 9.34 | Consolidated |
The financial information for Emcure Pharma is based on the Restated Consolidated Financial Statements as of and for the financial year ended March 31, 2024. The financial information for listed industry peers mentioned above, sourced from the audited financial statements of the respective companies for the financial year ended March 31, 2024, is on a consolidated basis (except for Abbott India Limited, where financial information is available only on a standalone basis) and is submitted to the Stock Exchanges.
Notes:
Emcure Pharma IPO Reviews, analysis and views by popular members. Read Emcure Pharmaceuticals Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 2 | 2 | 0 | 0 |
% | 50.00 | 50.00 | 0.00 | 0.00 |
Member | Review |
---|---|
Ankit Dhakad |
Apply for Listing Gain at Cut-off Price Apply for good listing gains as well as long term. The company has great brand value and financials. July 3, 2024 3:11:35 PM |
Jitendra pareek |
Apply for Listing Gain at Upper Price Band Good fundamentals and post ipo debt will be paid so valuation is reasonable July 1, 2024 9:07:22 PM |
Dhanvantri |
May Apply for Long Term at Upper Price Band Borrowing 2000 crores much higher HIV Monopoly pharma co Price Band much higher nothing left for listing gain May Apply June 29, 2024 10:37:17 AM |
Professōr Top Contributor (600+ Posts, 200+ Likes) |
May Apply for Short Term at Cut-off Price No superb listing gains expected , decent returns will be there June 28, 2024 10:16:19 AM |
Post Recommendation Manage Recommendations
Note:
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|